Abstract: An object of the present invention is to provide a crystalline saccharide having novel physical properties, a preparation and uses thereof. The present invention solves the above objects by providing a porous crystalline saccharide having a number of pores, a process for producing the same, comprising the step of keeping hydrous crystalline saccharide at an ambient temperature or higher in an organic solvent for the dehydration, and the use thereof.

Abstract: A kind of ascorbic acid derivates 3-O-glyco-L-ascorbic acid, their preparation methods, intermediates and uses in cosmetics. The derivates used as vitamin C precursors have better physiological effect than 2-O-?-D-glucopyranosyl ascorbic acid (AA-2G) and are more stable. Present compounds can be used in many fields, such as in cosmetics, pharmaceuticals, foodstuffs and livestock feed, and especially as whitening agents in cosmetics. The preparation method involves protecting the 5,6-dihydroxyl of ascorbic acid, then coupling with 1-haloacylglycosyl, obtaining the intermediate 3-O-(acylglycosyl)-(5,6-O-isopropylidine)-L-ascorbic acid, removing the isopropylidine and acyl from the intermediates, thereby obtaining the target substance.

Abstract: Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful products, such as fuels. For example, systems can use feedstock materials, such as cellulosic and/or lignocellulosic materials and/or starchy or sugary materials, to produce ethanol and/or butanol, e.g., by fermentation.

Abstract: The present invention relates to improved methods of purification of sugars and in particular to a method of preparing lactose. A low purity lactose source such as whey is subjected to a first demineralization step involving either ion-exchange or the addition of divalent metal cations, followed by a second demineralization step where alcohol is added. The invention also relates to lactose produced by this method and products comprising lactose produced by this method.

Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

Abstract: Granular sucralose-containing particles are produced by the methods of the invention, which involve coating sucralose from solution to form granules with this coated sucralose on an outer region thereof. The granules may incorporate agglomerated sucralose particles, with the solution-coated sucralose adding mass and generally resulting in a granule having a relatively smoothed and rounded. The granules have good flow properties, are low dusting, and resist caking. Methods of making the granules involve spraying an aqueous sucralose solution onto a fluidized bed of sucralose particles, followed by drying to form the granules.

Abstract: The present invention relates to a novel process for the chemical synthesis of ?-(1->6)-linked glucosamine disaccharides of the formula (1) and (intermediate) compounds relating to the process. According to further aspects the invention relates to compositions comprising the compounds and the use of the compounds in the synthesis of disaccharides and medicine.

Abstract: Improved processes for the purification of raw or refined sugar, or sucrose, to produce sucrose and sucrose-related products having substantially no inorganic impurities are described, wherein the processes include the use of both cation and anion exchange resins. In accordance with the process, a sucrose starting material, such as refined sugar or invert syrup, is dissolved in water at a temperature sufficient to dissolve the sucrose product and produce a low visicosity sucrose solution having not more than about 76 wt. % solids. Thereafter, the process includes contacting the low viscosity sucrose solution with one or more ion exchange resin beds, which can be separate or mixed, for a time sufficient to yield a highly-purified sucrose product that is substantially free of inorganic elemental impurities.

Abstract: The present invention relates to the use of at least one lactose-derived C-glycoside of general formula (I): as an agent for protecting and/or stimulating the activity and/or the proliferation of gamma-delta T lymphocyte cells (??T cells) in a composition containing a cosmetically or pharmaceutically acceptable medium. The composition will find applications for promoting skin tissue repair, for reequilibrating epidermal proliferation and differentiation disorders which appear with lack of sleep, and for improving the appearance of the head of hair and limiting hair loss.

Abstract: The invention relates to a shell catalyst containing ruthenium as an active metal, alone or together with at least one other metal of the auxiliary group IB, VIIB or VIII of the periodical system of the elements (CAS version), and applied to a carrier containing silicon dioxide as a carrier material. The invention also relates to a method for producing said shell catalyst, and to a method for hydrogenating an organic compound containing hydrogenable groups, preferably for hydrogenating a carbocyclic aromatic group to form the corresponding carbocyclic aliphatic groups or for hydrogenating aldehydes to form the corresponding alcohols, using the inventive shell catalyst. The invention further relates to the use of the inventive shell catalyst for hydrogenating an organic compound containing hydrogenable groups, preferably for hydrogenating a carbocyclic aromatic group to form the corresponding carbocyclic aliphatic groups or for hydrogenating aldehydes to form the corresponding alcohols.

Abstract: Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein.

Abstract: The invention relates to the use of compounds as new chiral selectors for separating the optical or enantiomeric isomers of a compound, wherein the chiral selector comprises at least one compound of formula (I): and at least one metal ion, for example Cu2+, Ni2+, Zn2+, Cd2+ or Co2+.

Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).

Abstract: Techniques for lung injury treatment are provided. For example, a technique for treating a lung injury in a patient includes the step of administering a therapeutically effective amount of a sophorolipid to the patient.

Abstract: The present invention relates to the use of a series of disaccharides, as well as of compositions containing them, for the preparation of a medicament for the treatment or prevention of a tendon, ligament or bone disease, disorder or injury. The present invention also relates to the new compositions comprising a disaccharide in combination with inulin polysulphate, a glycosamino-glycan, a growth factor or cells. The glycosaminoglycan is preferably chondroitin sulphate or hyaluronic acid and the growth fact is IFG-1.

Abstract: The present invention provides a fucoidan-derived low molecular weight compound with a good quality of taste, which has a specified structure and function and is free from problems in absorption, antigenicity, uniformity, an anticoagulant activity and so on, which problems arise when developing fucoidan, a sulfated polysaccharide having an extremely large molecular weight, as drugs or health foods. As a result of analyzing low molecular weight compounds obtained by acid hydrolysis of fucoidan, the inventors have identified fucoidan oligosaccharides (I) to (XI). Further, these oligosaccharides have been found to have anti-obesity and/or blood glucose elevation suppressing effects through inhibition of carbohydrate and/or lipid absorption as a result of ?-glucosidase inhibition and/or lipase inhibition.

Abstract: An immunogenic composition, and method of using the composition to elicit an immune response to Campylobacter jejuni. The composition is an isolated polysaccharide polymer composed of one or more forms of disaccharide polymers.

Abstract: Material characterized by that the material contains at least one biologically active di- or trisaccharide or higher oligosaccharide which is covalently bound via a spacer to cross-linked agarose.

Abstract: The present invention relates to novel compounds, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably a galectin-3.

Abstract: The present invention relates to a food compound comprising an emulsion containing triglyceride oils as well as a low-glycemic saccharose isomer.

Abstract: A pharmaceutical composition for use in the prevention and/or treatment of a neurodegenerative disorder comprising a compound comprised of one or more disaccharide units, the or each disaccharide unit comprising a uronate moiety linked to a glucosamine moiety, wherein the 2-O atom of the uronate moiety is substituted with a hydrogen atom, the 6-O atom of the glucosamine moiety is substituted with a sulphate group and the 2-N atom of the glucosamine moiety is substituted with an atom or group other than a sulphate group. The composition is particularly preferred for use in the prevention and/or treatment of Alzheimer's disease.

Abstract: A process is provided for preparing an iron sucrose complex, substantially free of excipients, for providing an iron sucrose complex co-precipitated with sucrose, and for providing iron sucrose complexes in aqueous solution.

Abstract: The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium.

Abstract: Solid pharmaceutical compositions for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like.

Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.

Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.

Abstract: The present invention relates to the tagging of Histidine in polypeptides with arylboronic acid tagging reagents. The present invention further describes methods and devices to identify proteins in a sample by isolating and identifying Histidine-comprising peptides from one protein sample or a pool of protein samples. The present invention further describes databases of Histidine-comprising peptides from in silico cleaved proteins and their use in the identification of proteins.

Abstract: An object of the present invention is to provide an agent for treating or preventing vasospasm. An object of the present invention is to provide an agent for treating or preventing cerebral vasospasm as well as arterial vasospasm. Further, an object of the present invention is to provide an agent for treating or preventing cerebral ischemia and cerebral infarction. The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media and to prevent or treat vasospasm and vasospasm-dependent diseases.

Abstract: The present invention includes a method of treating inflammation of the eye comprising administering to an eye of a patient suffering from inflammation of the eye, a composition comprising an aqueous solution of alginate having a minimum of about 50% mannuronate residues based upon the total number of saccharide monomeric units.

Abstract: The present invention provides a method for purifying sucralose-6-ester for use in making sucralose, wherein the method eliminates the need of an esterification process. In particular, ethyl acetate and ether are used to extract and purify sucralose-6-ester from a sucralose production intermediate composition comprising sucralose-6-ester.

Abstract: Present invention relates to disclosure of application of some innovative techniques useful for substantially improving process efficiency of production of chlorinated sucrose including their intermediates and derivatives. Application of mild methods of drying has been made for recovery of chlorinated sucrose or their intermediates and derivatives, in substantially pure form or with other solid chemical impurities, obtained at various stages in the process of production of chlorinated sucrose. Mild methods of drying included agitated thin film drying, spray drying, freeze drying and super critical extraction. Use of alkoxides has been introduced for deacylation instead of alkali hydroxides or alkaline earth hydroxides. Deacylation has been shown to be effective both, either before or after drying of the reaction mixture. Extraction and purification of desired products i.e.

Abstract: The present invention relates to novel compounds and the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably galectin-3.

Abstract: The present invention is directed to the introduction of molecules, including nucleic acids, carbohydrates, plant growth regulators and peptides into cells and tissues. The present invention is also directed to media and methods for enhancing embryogenic callus production of elite lines of soybean.

Abstract: The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.

Abstract: The present invention relates to an improved process for the preparation of Sucralose having purity of at least 99.6% comprising steps of (i) dissolving substantially impure Sucralose in water (ii) treating the solution obtained in step (i) with a partially water immiscible solvent (iii) washing the said solvent phase obtained in step (ii) with an amount of water sufficient to remove polar impurities (iv) crystallizing the product from partially water immiscible solvent (v) recrystallizing the solid obtained in step (iv) from water.

Abstract: An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit through a 1,6-linkage which connects C-6 of the first unit to C-1 of the second unit, wherein the 1,6-linkage comprises a phosphonate. Related methods of making such compounds, analogous compounds, or intermediates thereof are also disclosed.

Abstract: A composition includes at least one hydrophilic polymer containing primary (—NH2) and/or secondary (—NHR) amine groups and at least one saccharide containing a reducible function. A method of increasing the strength of paper includes the step of contacting the paper with a composition comprising (i) at least one hydrophilic polymer containing at least two groups which are independently the same or different a primary amine group or a secondary amine group and at least one saccharide containing a reducible function. A hydrogel composition is formed from a mixture of at least one hydrophilic polymer containing at least two groups which are independently the same or different a primary amine group or a secondary amine group and at least one saccharide containing a reducible function.

Abstract: A process for forming crystalline lactose suitable for use in a pharmaceutical formulation comprises subjecting a solution comprising a plurality of nanosized lactose particles to conditions sufficient to cause crystallization to occur on the nanosized lactose particles such that a plurality of lactose particles are formed therefrom having a median diameter ranging from about 4 ?m to about 20 ?m.

Abstract: This invention relates to a method for preparing a sucrose-6-ester.

Abstract: A process for producing lactose particles comprises combining a predetermined quantity of lactose seed particles to a first aqueous solution comprising a plurality of lactose particles to form a second solution, wherein the predetermined quantity of lactose seed particles is present in a well dispersed suspension and the first aqueous solution is saturated with said plurality of lactose particles; and subjecting the second solution to conditions sufficient to induce crystallization of the lactose seed particles to form a second plurality of lactose particles having a median particle size of about 25 microns to about 100 microns.

Abstract: Objects of the present invention are to provide a novel anhydrous crystalline ?-maltose, its preparation and uses. The present invention attains the above objects by providing an anhydrous crystalline ?-maltose with a melting point of 154 to 159° C.; a process for producing the same, comprising a step of keeping hydrous crystalline ?-maltose in an organic solvent at an ambient temperature or higher for the dehydration; and uses of the same.

Abstract: The invention relates to the use of prebiotics for the preparation of food or pharmaceutical compositions which are intended for the treatment and/or prevention of hyperglycaemic syndromes and, in particular, for the treatment of Type II diabetes and/or the prevention of the onset of Type II diabetes in patients with a predisposition to developing the type of diabetes. The invention also relates to the food and pharmaceutical compositions containing the prebiotics.

Abstract: The present invention describes a process for silylating polysaccharides, oligosaccharides or disaccharides or derivatives thereof by dissolving these in an ionic liquid and reacting them with a silylating agent.

Abstract: The present invention provides a method for purifying cellobiose which comprises the steps of (A) preparing a cellobiose-containing sugar solution; (B) increasing the rate of cellobiose present in the sugar solution relative to the total saccharides present therein up to at least 50% by mass; and (C) crystallizing cellobiose; and a method for preparing cellobiose having a high content of the ?-anomer thereof which comprises the step of drying a cellobiose-containing sugar solution having a rate of cellobiose of at least 90% by mass relative to the total saccharides present therein while maintaining the sugar solution at a temperature ranging from 80 to 95° C. These methods of the present invention permit the economical preparation of cellobiose having considerably improved purity and recovery rate, without using any complicated process. Moreover, the present invention also permits the preparation of cellobiose highly soluble in water.

Abstract: The invention includes methods for producing dianhydrosugar alcohol by providing an acid catalyst within a reactor and passing a starting material through the reactor at a first temperature. At least a portion of the staring material is converted to a monoanhydrosugar isomer during the passing through the column. The monoanhydrosugar is subjected to a second temperature which is greater than the first to produce a dianhydrosugar. The invention includes a method of producing isosorbide. An initial feed stream containing sorbitol is fed into a continuous reactor containing an acid catalyst at a temperature of less than 120° C. The residence time for the reactor is less than or equal to about 30 minutes. Sorbitol converted to 1,4-sorbitan in the continuous reactor is subsequently provided to a second reactor and is dehydrated at a temperature of at least 120° C. to produce isosorbide.

Abstract: This invention comprises an improved process for recovery and purification of DMF from an aqueous process stream containing DMF with or without inorganic impurities, particularly from process stream of a process of manufacture of the high intensity sweetener Trichlorogalactosucrose, by adsorption on an adsorbent having selective affinity towards dimethylformamide, followed by elution in pure form by eluting by an appropriate eluent, including methanol.

Abstract: A synthetic procedure for the preparation of non-animal based lactose from 4?-epimeric analogue of lactose by use of orthogonal protecting groups, formation of a suitable leaving group at the 4?-position, stereochemical inversion by nucleophilic attack and deprotection.

Abstract: A method of removing a carboxylic acid from a liquid that contains a tertiary amide solvent includes a step of contacting the liquid with an extraction medium comprising an amine. The amine is immiscible with both water and the tertiary amide solvent, and the contacting step forms a de-acidified phase containing the tertiary amide solvent and a phase containing the extraction medium and the carboxylic acid. Both the liquid that contains the tertiary amide solvent and the de-acidified phase may also contain a sucrose-6-acylate.

Abstract: An object of the invention is to provide a medical drug, a food and drink having a role in regulating the concentration of equal in vivo and being capable of taking for a long time with high safety and provide a selective medium for a microorganism having conversion ability to equal and a method of detecting the same. Provided are an equal concentration-raising or reducing agent containing a carbohydrate as an active ingredient; use of a carbohydrate for producing the equal concentration-raising or reducing agent; a method of raising or reducing the concentration of equal by administrating a carbohydrate in an effective dose; a selective medium containing a carbohydrate for a microorganism having conversion ability to equal; and a method of detecting a microorganism having conversion ability to equal by use of the selective medium.

Abstract: An inventive substrate is provided which includes a substrate compound of formula A-B1-B2-B3-B4: wherein A is a sugar moiety; B1 is a linker moiety allowing the conjugation of moiety A and the remaining structure of the substrate; B2 is a linker moiety with a free reactive amino group so as to be available for reaction with carboxylic acids or detectable tags; B3 contains a permanently charged element such as a quaternary ammonium group so as to increase sensitivity for mass spectrometry analysis; and B4 of various carbon length conferring specificity amongst individual substrates in detection methods. Also provided is a molecule of the formula B1-B2-B3-B4, with similar structural characteristics to an enzymatic product produced by the action of a target enzyme on an inventive substrate. Further provided are methods for using inventive substrates for detecting enzymatic activity.